Hyperglycemia and the pathogenesis of atherosclerosis: Lessons from murine models

European Journal of Endocrinology

Volumn 140, Issue 1, 1999, Pages 1-3

  Vischer, Ulrich M ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E; GLUCOSE; LACTOFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERGLYCEMIA; HYPERLIPIDEMIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ARTERIOSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERGLYCEMIA; HYPERLIPIDEMIAS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC;

EID: 0032973720     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1400001     Document Type: Short Survey

References (12)

1. Breslow JL. Mouse models of atherosclerosis. Science 1996 272 685-688.
2. Kunjathoor VV, Wilson DL & LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. Journal of Clinical Investigation 1996 97 1767-1773.
3. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Versuyft JG, Rubin EM & Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992 71 343-353.
4. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D & Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 1998 4 1025-1031.
5. Brownlee M. Glycation and diabetic complications. Diabetes 1994 43 836-841.
6. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M & Stern D. RAGE. A novel cellular receptor for advanced glycation endproducts. Diabetes 1996 45 (Suppl 3) S77-S80.
7. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D & Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. Journal of Clinical Investigation 1994 269 9889-9897.
8. Schmidt AM, Hori O, Chen JF, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J & Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. Journal of Clinical Investigation 1995 96 1395-1403.
9. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D & Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation endproducts blocks hyperpermeability in diabetic rats. Journal of Clinical Investigation 1996 97 238-243.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993 329 977-986.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853.
12. Lopez-Liuchi JV & Meier CA. Therapy for type 2 diabetes: where do we stand after the UK Prospective Diabetes Study? European Journal of Endocrinology 1999 140 4-6.